Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellectis, a genome engineering company, has terminated the non-exclusive license it had granted to Genoway, a developer of genetically modified animal models, in 2001 for certain uses of homologous recombination. The termination is effective as of December 30, 2008.
Subscribe to our email newsletter
The license authorized making and selling cellular and animal models in a restricted field, for research uses only expressly excluding the use of such product for any commercial application.
Genoway challenged this termination in court. Cellectis intends to obtain proper compensation for the damages that it deems having suffered from the uses made by Genoway outside the licensed field.
The licensed patents cover certain uses of homologous recombination, in particular for the targeted insertion of DNA sequences made functional in eukaryotic genomes, such as that of animals for example.
The knock-in processes, currently used to obtain cellular and animal models, including mouse models, such as mice that are humanized for a chosen gene, are covered by these patents.